Search Results - "Kortuem, K. Martin"

Carfilzomib by Kortuem, K. Martin, Stewart, A. Keith

“…This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for…”
Get full text

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma by Zhu, Yuan Xiao, Kortuem, K. Martin, Stewart, A. Keith

“…Abstract Although several mechanisms have been proposed to explain the activity of thalidomide, lenalidomide and pomalidomide in multiple myeloma (MM),…”
Get full text

Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements by Egan, Jan B, Barrett, Michael T, Champion, Mia D, Middha, Sumit, Lenkiewicz, Elizabeth, Evers, Lisa, Francis, Princy, Schmidt, Jessica, Shi, Chang-Xin, Van Wier, Scott, Badar, Sandra, Ahmann, Gregory, Kortuem, K Martin, Boczek, Nicole J, Fonseca, Rafael, Craig, David W, Carpten, John D, Borad, Mitesh J, Stewart, A Keith

“…Liposarcoma is the most common soft tissue sarcoma, but little is known about the genomic basis of this disease. Given the low cell content of this tumor type,…”
Get full text

Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease by EGAN, Jan B, KORTUEM, K. Martin, LIANG, Winnie S, CRAIG, David W, CARPTEN, John D, STEWART, A. Keith, KURDOGLU, Ahmet, IZATT, Tyler, ALDRICH, Jessica, REIMAN, Rebecca, PHILLIPS, Lori, BAKER, Angela, SHI, Chang-Xin, SCHMIDT, Jessica

Get full text

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma by Zhu, Yuan Xiao, Braggio, Esteban, Shi, Chang-Xin, Kortuem, K. Martin, Bruins, Laura A., Schmidt, Jessica E., Chang, Xiu-Bao, Langlais, Paul, Luo, Moulun, Jedlowski, Patrick, LaPlant, Betsy, Laumann, Kristina, Fonseca, Rafael, Bergsagel, P. Leif, Mikhael, Joseph, Lacy, Martha, Champion, Mia D., Stewart, A. Keith

“…Cereblon (CRBN) mediates immunomodulatory drug (IMiD) action in multiple myeloma (MM). Using 2 different methodologies, we identified 244 CRBN binding proteins…”
Get full text

Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by 18F-FDG and 11C-methionine PET/CT by Heidemeier, Anke, Schloetelburg, Wiebke, Thurner, Annette, Metz, Corona, Heidemeier, Heike, Rasche, Leo, Martin Kortuem, K., Boeckle, David, Weiland, Elisabeth, Benkert, Thomas, Nickel, Dominik, Werner, Rudolf, Buck, Andreas Konrad, Bley, Thorsten Alexander

“…[Display omitted] •Multi-parametric whole-body MRI facilitates a reproducible, standardized whole-body MR analysis in multiple myeloma.•A prototypical…”
Get full text

The clinical significance of cereblon expression in multiple myeloma by Schuster, Steven R, Kortuem, K. Martin, Zhu, Yuan Xiao, Braggio, Esteban, Shi, Chang-Xin, Bruins, Laura A, Schmidt, Jessica E, Ahmann, Greg, Kumar, Shaji, Rajkumar, S. Vincent, Mikhael, Joseph, LaPlant, Betsy, Champion, Mia D, Laumann, Kristina, Barlogie, Bart, Fonseca, Rafael, Bergsagel, P. Leif, Lacy, Martha, Stewart, A. Keith

“…Abstract Cereblon (CRBN) mediates immunomodulatory drug (IMiD) action in multiple myeloma (MM). We demonstrate here that no patient with very low CRBN…”
Get full text

Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma by Kortuem, K. Martin, Zidich, Kaitlyn, Schuster, Steven R, Khan, Meaghan L, Jimenez-Zepeda, Victor H, Mikhael, Joseph R, Fonseca, Rafael, Stewart, A. Keith

“…Micro-Abstract This is the first comparative analysis of single-agent drug activity in multiple myeloma. Our work suggests that a cutoff of 22% single-agent…”
Get full text

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma by Lee, Holly, Ahn, Sungwoo, Maity, Ranjan, Leblay, Noemie, Ziccheddu, Bachisio, Truger, Marietta, Chojnacka, Monika, Cirrincione, Anthony, Durante, Michael, Tilmont, Remi, Barakat, Elie, Poorebrahim, Mansour, Sinha, Sarthak, McIntyre, John, M.Y. Chan, Angela, Wilson, Holly, Kyman, Shari, Krishnan, Amrita, Landgren, Ola, Walter, Wencke, Meggendorfer, Manja, Haferlach, Claudia, Haferlach, Torsten, Einsele, Hermann, Kortüm, Martin K., Knop, Stefan, Alberge, Jean Baptiste, Rosenwald, Andreas, Keats, Jonathan J., Rasche, Leo, Maura, Francesco, Neri, Paola, Bahlis, Nizar J.

“…B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen…”
Get full text

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice by Zhou, Xiang, Rasche, Leo, Kortüm, K Martin, Mersi, Julia, Einsele, Hermann

“…The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric antigen receptor modified T cells and bispecific antibodies are…”
Get full text

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma by Da Vià, Matteo C., Dietrich, Oliver, Truger, Marietta, Arampatzi, Panagiota, Duell, Johannes, Heidemeier, Anke, Zhou, Xiang, Danhof, Sophia, Kraus, Sabrina, Chatterjee, Manik, Meggendorfer, Manja, Twardziok, Sven, Goebeler, Maria-Elisabeth, Topp, Max S., Hudecek, Michael, Prommersberger, Sabrina, Hege, Kristen, Kaiser, Shari, Fuhr, Viktoria, Weinhold, Niels, Rosenwald, Andreas, Erhard, Florian, Haferlach, Claudia, Einsele, Hermann, Kortüm, K. Martin, Saliba, Antoine-Emmanuel, Rasche, Leo

“…B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker for tumor load in multiple myeloma (MM). We report a case of…”
Get full text

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab by García-Guerrero, Estefanía, Götz, Ralph, Doose, Sören, Sauer, Markus, Rodríguez-Gil, Alfonso, Nerreter, Thomas, Kortüm, K. Martin, Pérez-Simón, José A., Einsele, Hermann, Hudecek, Michael, Danhof, Sophia

“…Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease. This situation…”
Get full text

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma by Giesen, Nicola, Chatterjee, Manik, Scheid, Christof, Poos, Alexandra M., Besemer, Britta, Miah, Kaya, Benner, Axel, Becker, Nicole, Moehler, Thomas, Metzler, Ivana, Khandanpour, Cyrus, Seidel-Glaetzer, Andrea, Trautmann-Grill, Karolin, Kortüm, K. Martin, Müller-Tidow, Carsten, Mechtersheimer, Gunhild, Goeppert, Benjamin, Stenzinger, Albrecht, Weinhold, Niels, Goldschmidt, Hartmut, Weisel, Katja, Raab, Marc S.

“…•Combined BRAF/MEK inhibition shows high response rates in relapsed refractory multiple myeloma with activating BRAF mutations.•RAS mutations and structural…”
Get full text

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma by Rasche, Leo, Kortüm, K Martin, Raab, Marc S, Weinhold, Niels

“…Myeloma is characterized by extensive inter-patient genomic heterogeneity due to multiple different initiating events. A recent multi-region sequencing study…”
Get full text

Real-World Treatment Patterns of Patients Initiating Third-Line Therapy in Relapsed or Refractory Multiple Myeloma in Europe by Lehne, Moritz, Kortuem, K. Martin, Zamagni, Elena, d'Estrube, Tim, Shukla, Soham, Zhuleku, Evi, Ghiani, Marco, Hanna, Maya, Maywald, Ulf, Wilke, Thomas, Perera, Sue

Get full text

Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression by Dahlhoff, Julia, Manz, Hannah, Steinfatt, Tim, Delgado-Tascon, Julia, Seebacher, Elena, Schneider, Theresa, Wilnit, Amy, Mokhtari, Zeinab, Tabares, Paula, Böckle, David, Rasche, Leo, Martin Kortüm, K., Lutz, Manfred B., Einsele, Hermann, Brandl, Andreas, Beilhack, Andreas

“…Multiple myeloma remains a largely incurable disease of clonally expanding malignant plasma cells. The bone marrow microenvironment harbors treatment-resistant…”
Get full text

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma by Leipold, Alexander M., Werner, Rudolf A., Düll, Johannes, Jung, Pius, John, Mara, Stanojkovska, Emilia, Zhou, Xiang, Hornburger, Hannah, Ruckdeschel, Anna, Dietrich, Oliver, Imdahl, Fabian, Krammer, Tobias, Knop, Stefan, Rosenwald, Andreas, Buck, Andreas, Sander, Leif Erik, Einsele, Hermann, Kortüm, K. Martin, Saliba, Antoine-Emmanuel, Rasche, Leo

“…Pseudo-progression and flare-up phenomena constitute a novel diagnostic challenge in the follow-up of patients treated with immune-oncology drugs. We present a…”
Get full text

MYC dysregulation in the progression of multiple myeloma by Misund, Kristine, Keane, Niamh, Stein, Caleb K., Asmann, Yan W., Day, Grady, Welsh, Seth, Van Wier, Scott A., Riggs, Daniel L., Ahmann, Greg, Chesi, Marta, Viswanatha, David S., Kumar, Shaji K., Dispenzieri, Angela, Gonzalez-Calle, Veronica, Kyle, Robert A., O’Dwyer, Michael, Rajkumar, S. Vincent, Kortüm, K. Martin, Keats, J. Jonathan, Fonseca, Rafael, Stewart, A. Keith, Kuehl, W. Michael, Braggio, Esteban, Bergsagel, P. Leif

Get full text

Cereblon enhancer methylation and IMiD resistance in multiple myeloma by Haertle, Larissa, Barrio, Santiago, Munawar, Umair, Han, Seungbin, Zhou, Xiang, Vogt, Cornelia, Fernández, Rafael Alonso, Bittrich, Max, Ruiz-Heredia, Yanira, Da Viá, Matteo, Zovko, Josip, Garitano-Trojaola, Andoni, Bolli, Niccolò, Ruckdeschel, Anna, Stühmer, Thorsten, Chatterjee, Manik, Kull, Miriam, Krönke, Jan, Agirre, Xabier, Martin-Subero, Jose I., Raab, Peter, Einsele, Hermann, Rasche, Leo, Martinez-Lopez, Joaquin, Haaf, Thomas, Kortüm, K. Martin

“…Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM), the second most frequent…”
Get full text

Spectrum and functional validation of PSMB5 mutations in multiple myeloma by Barrio, Santiago, Stühmer, Thorsten, Da-Viá, Matteo, Barrio-Garcia, Clara, Lehners, Nicola, Besse, Andrej, Cuenca, Isabel, Garitano-Trojaola, Andoni, Fink, Severin, Leich, Ellen, Chatterjee, Manik, Driessen, Christoph, Martinez-Lopez, Joaquin, Rosenwald, Andreas, Beckmann, Roland, Bargou, Ralf C., Braggio, Esteban, Stewart, A. Keith, Raab, Marc S., Einsele, Hermann, Kortüm, K. Martin

“…Despite an increasing number of approved therapies, multiple myeloma (MM) remains an incurable disease and only a small number of patients achieve prolonged…”
Get full text